Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

PHASE3CompletedINTERVENTIONAL

Enrollment

15,000

Participants

Timeline

Start Date

January 8, 2003

Primary Completion Date

December 8, 2004

Study Completion Date

December 8, 2004

Conditions

Prostate Cancer

Interventions

DRUG

rofecoxib

DRUG

Comparator: placebo (unspecified)

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00060476 - Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) | Biotech Hunter | Biotech Hunter